Responsibly Advancing the Use of AI in Clinical Trials: Current landscape, Common Misconceptions and Future Opportunities
Discover an informative webinar delving into the transformative role of artificial intelligence (AI) in clinical trials: where the industry is currently at, common misconceptions in leveraging AI, proactively tackling the potential for bias and navigating the current regulatory landscape.
In its current state, AI can help optimize operations, integrate platforms, strengthen patient privacy and improve data quality while reducing the risk of human error in clinical trials. AI must be used responsibly and be governed by the highest ethical principles when used in clinical trials. This includes data privacy considerations, and efforts to reduce bias in algorithm performance. Following current regulatory guidance and a company code of conduct, AI, machine learning and deep learning capabilities are responsible across more than 600 ongoing, active clinical trials.
Join this webinar to gain an understanding of the responsible application of AI-enabled algorithms in clinical trial endpoint collection and data analysis.
Attendees will learn:
- An overview of AI’s transformative role in clinical trials, addressing industry status, misconceptions, bias and regulatory issues
- AI’s impact on improving operations, patient privacy, data quality and reducing human error in clinical trials
- Emphasis on ethical AI usage, focusing on data privacy and algorithm bias reduction
Speakers
Todd Rudo, M.D.
Chief Medical Officer at Clario
As Clario’s Chief Medical Officer, Dr. Todd Rudo provides medical and scientific leadership across the organization. Passionate about leveraging Clario’s scientific resources to support customer success, Dr. Rudo has focused efforts on developing expertise across a range of therapeutic areas. His team provides expert consulting to clients on scientific and regulatory strategy, and ensures Clario’s product portfolio is scientifically robust, generating high quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while also maintaining focus on patient and site burden. With nearly 20 years of clinical cardiology and pharmaceutical research experience, Dr. Rudo has focused predominantly on drug safety, working across a wide range of therapeutic areas.
Lauren Misztal
Senior Vice President, General Counsel at Clario
Lauren Misztal is a business-oriented and solutions-driven legal advisor who draws on close to two decades of experience successfully resolving complex legal and regulatory issues. Prior to joining Clario, Lauren held senior legal and compliance roles at Mallinckrodt Pharmaceuticals and McKesson Corporation and was an associate and Of Counsel at Quinn Emanuel LLP. Lauren began her legal career as a trial attorney at the US Department of Justice after clerking for a federal judge in Washington, DC.
She received her JD from Georgetown University Law Center and her bachelor’s degree from Georgetown University. Prior to attending law school, Lauren was a financial analyst at Goldman Sachs. As Clario’s General Counsel, Lauren focuses on setting the Company’s global legal strategy and leads teams dedicated to supporting our commercial relationships, counselling on data privacy regulations and mitigating risk.
Gaurav Josan
Senior Vice President, R&D at Clario
Gaurav Josan is an accomplished technology professional with extensive experience working in the pharmaceutical and medical imaging industries. She has spent her career focused on clinical research and is an expert in building and leading software implementation teams. Since 2018, she has overseen the implementation of more than 30 AI models across the Clario technology platform with a steady focus on effectively expediting data collection, decreasing variability, strengthening patient privacy and increasing the quality of data.